Search Results for keywords:"USPTO"

The United States Patent and Trademark Office (USPTO) is seeking public comments on its information collection for the Patents for Humanity Program and Trademarks for Humanity Program, which are initiatives aimed at encouraging the use of patents and trademarks to address humanitarian issues. The Patents for Humanity Program incentivizes patent holders to distribute technology for humanitarian purposes, offering award certificates that can accelerate patent matters. In 2023, the USPTO introduced the Trademarks for Humanity Program, which recognizes brand owners using trademarks to tackle societal challenges. Public comments are invited on these programs to help the USPTO assess and reduce reporting burdens.

The United States Patent and Trademark Office (USPTO) is seeking public comments on the issue of secondary trademark infringement in the e-commerce sector. This request was initially published in the Federal Register on November 13, 2020, and invites insights from various stakeholders, including intellectual property rights holders and online marketplaces, on how traditional trademark laws apply to online platforms. The period for submitting comments has been extended until January 25, 2021, to allow more time for interested parties to participate. The USPTO is particularly interested in feedback on the effectiveness of current laws and any recommendations for improvement.

The United States Patent and Trademark Office (USPTO) is asking for public comments on renewing and revising existing rules for tracking and managing how lawyers and agents behave while representing clients. This involves keeping accurate records about client properties and reporting any misconduct. These rules help maintain the integrity of professional conduct in the USPTO and can lead to suspensions or other penalties if violated. Public comments are invited to evaluate the necessity and efficiency of these rules, with a deadline for submissions set for May 12, 2025.

The United States Patent and Trademark Office (USPTO) is making minor corrections to a rule about patent fees that was previously published. These changes involve fixing typos and other small errors in the document, ensuring everything is accurate without changing the rule's substance. The corrections aim to prevent confusion by providing the correct information before the rule becomes effective on January 19, 2025. These amendments have been made without public comment since they are administrative and do not alter any major aspects of the rule.

The Food and Drug Administration (FDA) has determined the regulatory review period for the drug XTAMPZA ER, which is used for managing severe pain requiring long-term opioid treatment. This review is necessary for a possible extension of the drug's patent, as requested by Collegium Pharmaceutical, Inc. The review period comprises 3,214 days, with 2,712 days for testing and 502 days for approval. The FDA invites comments on this determination and allows for petitions if there are disagreements concerning the information or the due diligence during the review process.

The United States Patent and Trademark Office (USPTO) has officially ended the Climate Change Mitigation Pilot Program. The program, which allowed for patent applications to be processed more quickly if they were related to climate change solutions, was suspended in January 2025 after the executive order that supported it was revoked. Any petitions to join the program submitted after this date will not be considered. The USPTO encourages patent applicants seeking expedited processing to apply through the Track One Program for prioritized examination.

The United States Patent and Trademark Office (USPTO) is seeking public comments on the renewal of an information collection related to the "first inventor to file" system. Initially, comments were collected in October 2024, allowing a 60-day period, and now an additional 30 days are provided for further comments. This collection, necessary for certain patent applications filed after March 16, 2013, helps determine if the applications comply with specific patent laws changed by the America Invents Act. The review addresses the burden on the public, and public input can be submitted through the website reginfo.gov.

The United States Patent and Trademark Office (USPTO) made corrections to a rule regarding trademark fees that was published on November 18, 2024. These changes fix minor errors in the rule's language without altering its substance to prevent confusion among those affected. The corrections clarify the references in the rule and ensure the right fees and requirements for different types of trademark applications are clear. These updates, which do not add any new rules or charges, take effect on January 18, 2025.

The United States Patent and Trademark Office (USPTO) is requesting public comments on the extension and revision of an existing information collection related to "Representative and Address Provisions." According to the Paperwork Reduction Act of 1995, they are inviting comments to be submitted before March 16, 2021. The collection includes various forms and procedures for managing power of attorney and correspondence addresses related to patent applications. USPTO is seeking feedback on the necessity, burden, and efficacy of the information collection methods, including electronic submission options.

The United States Patent and Trademark Office (USPTO) has granted a one-year interim extension for U.S. Patent No. 7,534,790, which covers the drug vernakalant hydrochloride. The extension was necessary because the regulatory review by the Food and Drug Administration (FDA) will extend beyond the patent's expiration date of March 31, 2021. Correvio International Sàrl, the patent owner, applied for this third interim extension as allowed under U.S. patent law for certain cases where market approval is pending. This extension ensures the patent remains valid while the review process continues.